FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

GE Recalls Unstable Nuclear Medicine Devices

[ Price : $8.95]

GE HealthCare recalls its Nuclear Medicine 600 and 800 Series systems after identifying an issue with two mechanisms that prevent ...

Drug R&D Cant Justify High Prices: Study

[ Price : $8.95]

UK-based researchers say their analysis of drug company financial records doesnt support company claims that high drug prices are ...

Further FDA Opioid Crisis Strategies: Califf

[ Price : $8.95]

FDA commissioner Robert Califf outlines ways the agency is taking additional steps as part of its response to the nations opioid c...

30 New Product-Specific Guidances Out

[ Price : $8.95]

FDA releases a batch of 30 new and revised product-specific guidances to aid in the development of generic drugs.

Pfizer Says Talzenna Prostate Cancer Study Positive

[ Price : $8.95]

Pfizer says FDA has granted priority review for its sNDA for Talzenna and Xtandi which showed positive results in a Phase 3 study ...

FDA Approves BioVex BLA Supplement

[ Price : $8.95]

FDA approves a BioVex BLA supplement to update the adverse drug reactions for its talimogene laherparepvec melanoma treatment.

Merit Medical Breakthrough Status for Scout Device

[ Price : $8.95]

FDA grants Merit Medical Systems a breakthrough device designation for its Scout MD Surgical Guidance System.

GAO Identifies FDA Gaps in IRB Oversight

[ Price : $8.95]

The Government Accountability Office calls on FDA and the HHS Office of Human Research Protections to take steps to improve their ...

FDA Pushed Into Accelerated Approval Pricing Model

[ Price : $8.95]

HHS directs FDA to work with CMS Innovation Center to test a proposed model that would adjust Medicare payments for accelerated ap...

Regulatory Review Period for Bayers Aliqopa

[ Price : $8.95]

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Bayers Aliqopa (copanlisib ...